《2024年中国脑卒中防治报告》概要

doi:10.3969/j.issn.1006-7795.2025.06.001

摘要/Abstract

摘要： 近年来，中国脑卒中整体发病率较前略有下降，但依然是我国居民的头号健康威胁。我国脑卒中疾病负担重，流行病学特征明显，主要危险因素普遍存在且控制不佳。但与此同时，国家大力推进脑卒中防治体系建设进展，以及支持脑卒中防治相关科研课题，使得我国脑卒中诊疗水平持续进步。我国脑卒中防治工作道阻且长。本篇概要从我国脑卒中的流行病学、危险因素、诊疗进展、防治体系建设进展，以及卒中中心建设进展五个方面梳理总结了2023年中国脑卒中防治工作状况，旨在为我国的脑卒中临床实践和管理提供参考和依据。

关键词: 脑卒中, 发病率, 患病率, 流行病学, 危险因素, 中国

Abstract: lthough China has a slight decline in stroke incidence in recent years, it still seems to be the leading health threat to Chinese citizens. China continues to bear a heavy stroke burden which has distinct epidemiological characteristics, while major risk factors remain prevalent and poorly controlled. Markedly, the government is putting effort into advancing the stroke prevention and treatment system, meanwhile, continuously funding cerebrovascular disease research, and driving steady improvements in diagnosis and treatment capabilities. However, stroke prevention and control work in China still faces considerable challenges. This report systematically reviews the current state of stroke prevention and treatment in China during 2023 from five perspectives: epidemiological characteristics, risk factors, diagnostic and therapeutic advances, prevention system development and stroke center construction, aiming to provide references for clinical practice.

Key words: stroke, incidence, prevalence, epidemiology, risk factor, China

中图分类号:

R743

国家卫生健康委加强脑卒中防治工作减少百万新发残疾工程专家委员会, 吉训明. 《2024年中国脑卒中防治报告》概要[J]. 首都医科大学学报, 2025, 46(6): 947-960.

Stroke Prevention Project, National Health Commission, Ji Xunming. Brief report on stroke prevention and treatment in China,2024[J]. Journal of Capital Medical University, 2025, 46(6): 947-960.

参考文献

［1］Wang Y J, Li Z X, Gu H Q, et al. China stroke statistics: an update on the 2019 report from the national center for healthcare quality management in neurological diseases, China national clinical research center for neurological diseases, the Chinese stroke association, national center for chronic and non-communicable disease control and prevention, Chinese center for disease control and prevention and institute for global neuroscience and stroke collaborations［J］. Stroke Vasc Neurol, 2022, 7(5): 415－450.
［2］Institute for Health Metrics and Evaluation (IHME). GBD Results［R］. Seattle: University of Washington, 2025.
［3］Ma Q F, Li R, Wang L J, et al. Temporal trend and attributable risk factors of stroke burden in China, 1990－2019: an analysis for the Global Burden of Disease Study 2019［J］. Lancet Public Health, 2021, 6(12): e897－e906.
［4］Xu J, Zhang X, Jin A M, et al. Trends and risk factors associated with stroke recurrence in China, 2007－2018［J］. JAMA Netw Open, 2022, 5(6): e2216341.
［5］国家卫生健康委员会. 2023中国卫生健康统计年鉴［M］. 北京: 中国协和医科大学出版社, 2024.
［6］Tu W J, Chao B H, Ma L, et al. Case-fatality, disability and recurrence rates after first-ever stroke: a study from bigdata observatory platform for stroke of China［J］. Brain Res Bull, 2021, 175: 130－135.
［7］Tu W J, Zhao Z P, Yin P, et al. Estimated burden of stroke in China in 2020［J］. JAMA Netw Open, 2023, 6(3): e231455.
［8］Jin C Y, Lai Y X, Li Y Z, et al. Changes in the prevalence of diabetes and control of risk factors for diabetes among Chinese adults from 2007 to 2017: an analysis of repeated national cross-sectional surveys［J］. J Diabetes, 2024, 16(2): e13492.
［9］Shi Q Y, Nong K L, Vandvik P O, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials［J］. BMJ, 2023, 381: e074068.
［10］Xia Q H, Chen Y Q, Yu Z J, et al. Prevalence, awareness, treatment, and control of dyslipidemia in Chinese adults: a systematic review and meta-analysis［J］. Front Cardiovasc Med, 2023, 10: 1186330.
［11］Yang X H, Zhang B L, Cheng Y, et al. Association of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: a systemic review and meta-analysis［J］. Atherosclerosis, 2023, 371: 21－31.
［12］Liu Y T, Jin X L, Fu K L, et al. Non-traditional lipid profiles and the risk of stroke: a systematic review and meta-analysis［J］. Nutr Metab Cardiovasc Dis, 2023, 33(4): 698－714.
［13］Zhang T T, Liang Z R, Lin T F, et al. Cost-effectiveness of folic acid therapy for primary prevention of stroke in patients with hypertension［J］. BMC Med, 2022, 20(1): 407.
［14］Lu X T, Wang Y N, Mo Q W, et al. Effects of low-dose B vitamins plus betaine supplementation on lowering homocysteine concentrations among Chinese adults with hyperhomocysteinemia: a randomized, double-blind, controlled preliminary clinical trial［J］. Eur J Nutr, 2023, 62(4): 1599－1610.
［15］Shi S B, Tang Y H, Zhao Q Y, et al. Prevalence and risk of atrial fibrillation in China: a national cross-sectional epidemiological study［J］. Lancet Reg Health West Pac, 2022, 23: 100439.
［16］Wei Y, Zhou G Q, Wu X Y, et al. Latest incidence and electrocardiographic predictors of atrial fibrillation: a prospective study from China［J］. Chin Med J, 2023, 136(3): 313－321.
［17］Shang L X, Zhang Y J, Zhao Y, et al. Contemporary oral anticoagulant therapy of patients with atrial fibrillation in China: status, obstacles, and strategies for improvement［J］. Biosci Trends, 2022, 16(5): 317－329.
［18］Fan J H, Li X G, Yu X Y, et al. Global burden, risk factor analysis, and prediction study of ischemic stroke, 1990－2030［J］. Neurology, 2023, 101(2): e137－e150.
［19］Liang T, Xie C P, Lv B J, et al. Age at smoking initiation and smoking cessation influence the incidence of stroke in China: a 10-year follow-up study［J］. J Thromb Thrombolysis, 2023, 56(1): 175－187.
［20］中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国缺血性卒中和短暂性脑缺血发作二级预防指南2022［J］. 中华神经科杂志, 2022, 55(10): 1071－1110.
［21］Zuo X, Zhao R, Wu M, et al. Soy consumption and the risk of type 2 diabetes and cardiovascular diseases: a systematic review and Meta-analysis［J］. Nutrients, 2023, 15(6)：1358.
［22］Wang L M, Zhou B, Zhao Z P, et al. Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004－18［J］. Lancet, 2021, 398(10294): 53－63.
［23］Yawoot N, Govitrapong P, Tocharus C, et al. Ischemic stroke, obesity, and the anti-inflammatory role of melatonin［J］. Biofactors, 2021, 47(1): 41－58.
［24］Ye J Y, Hu Y J, Chen X R, et al. Association between the weight-adjusted waist index and stroke: a cross-sectional study［J］. BMC Public Health, 2023, 23(1): 1689.
［25］Qi W W, Ma J, Guan T J, et al. Risk factors for incident stroke and its subtypes in China: a prospective study［J］. J Am Heart Assoc, 2020, 9(21): e016352.
［26］Luo L, Meng H N, Wang Z W, et al. Effect of high-intensity exercise on cardiorespiratory fitness in stroke survivors: a systematic review and meta-analysis［J］. Ann Phys Rehabil Med, 2020, 63(1): 59－68.
［27］Wu H, Zhang B Y, Wei J, et al. Short-term effects of exposure to ambient PM1, PM2.5, and PM10 on ischemic and hemorrhagic stroke incidence in Shandong province, China［J］. Environ Res, 2022, 212(Part C): 113350.
［28］Shu M J, Li J R, Zhu Y C, et al. Migraine and ischemic stroke: a mendelian randomization study［J］. Neurol Ther, 2022, 11(1): 237－246.
［29］Yuan J, Lu Z K, Xiong X M, et al. Age and geographic disparities in acute ischaemic stroke prehospital delays in China: a cross-sectional study using national stroke registry data［J］. Lancet Reg Health West Pac, 2023, 33: 100693.
［30］Chen Y J, Ying M, Chen L H. Application effect of prehospital-hospital integrated emergency nursing in patients with acute cerebral infarction［J］. Biotechnol Genet Eng Rev, 2024, 40(4): 4407－4419.
［31］Song H Q, Wang Y, Ma Q F, et al. Efficacy and safety of recombinant human prourokinase in the treatment of acute ischemic stroke within 4.5 hours of stroke onset: a phase 3 randomized clinical trial［J］. JAMA Netw Open, 2023, 6(7): e2325415.
［32］Wang Y J, Li S Y, Pan Y S, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial［J］. Lancet, 2023, 401(10377): 645－654.
［33］Chen H S, Cui Y, Zhou Z H, et al. Dual antiplatelet therapy vs alteplase for patients with minor nondisabling acute ischemic stroke: the ARAMIS randomized clinical trial［J］. JAMA, 2023, 329(24): 2135－2144.
［34］Bai X S, Zhang X, Gong H Z, et al. Different types of percutaneous endovascular interventions for acute ischemic stroke［J］. Cochrane Database Syst Rev, 2023, 5(5): CD014676.
［35］Zhao C H, Hu T, Kong W L, et al. First-pass effect in patients with acute basilar artery occlusions undergoing stent retriever thrombectomy［J］. J Neurosurg, 2023, 138(3): 693－700.
［36］Huo X C, Ma G T, Tong X, et al. Trial of endovascular therapy for acute ischemic stroke with large infarct［J］. N Engl J Med, 2023, 388(14): 1272－1283.
［37］Li Q, Abdalkader M, Siegler J E, et al. Mechanical thrombectomy for large ischemic stroke: a systematic review and meta-analysis［J］. Neurology, 2023, 101(9): e922－e932.
［38］Deng Q W, Zhang L, Liu Y K, et al. Effect of time window on endovascular thrombectomy with or without intravenous thrombolysis in acute ischemic stroke: results from DIRECT-MT［J］. Cerebrovasc Dis, 2024, 53(2): 176－183.
［39］Kang Z M, Wu L S, Sun D, et al. Proximal hyperdense middle cerebral artery sign is associated with increased risk of asymptomatic hemorrhagic transformation after endovascular thrombectomy: a multicenter retrospective study［J］. J Neurol, 2023, 270(3): 1587－1599.
［40］Sarraj A, Hassan A E, Abraham M G, et al. Trial of endovascular thrombectomy for large ischemic strokes［J］. N Engl J Med, 2023, 388(14): 1259－1271.
［41］Wang Y, Ma H R, Zhang Q H, et al. Factors affecting the outcomes of tirofiban after endovascular treatment in acute ischemic stroke: experience from a single center［J］. CNS Neurosci Ther, 2023, 29(3): 957－967.
［42］Liu H H, Jing J, Wang A X, et al. Stroke recurrence and antiplatelets in posterior versus anterior circulation minor stroke or transient ischemic attack［J］. Stroke, 2023, 54(4): 964－972.
［43］Zhang J, Wang A X, Tian X, et al. Impact of body mass index on efficacy and safety of ticagrelor versus clopidogrel in patients with minor stroke or transient ischemic attack［J］. CMAJ, 2023, 195(26): E897－E904.
［44］Jing J, Xie X W, Johnston S C, et al. Genotype-guided dual antiplatelet use for transient ischemic attack and minor stroke by imaging status: subgroup analysis of the CHANCE-2 trial［J］. Ann Neurol, 2023, 93(4): 783－792.
［45］Zhang X G, Jiang S S, Xue J, et al. Personalized antiplatelet therapy guided by clopidogrel pharmacogenomics in acute ischemic stroke and transient ischemic attack: a prospective, randomized controlled trial［J］. Front Pharmacol, 2022, 13: 931405.
［46］Zhai Y J, Shi M Y, Liu Y, et al. Magnitude of systolic blood pressure reduction and early achieved blood pressure and clinical outcomes after acute ischemic stroke［J］. J Am Heart Assoc, 2023, 12(20): e030692.
［47］Du L Z, Zhang Y Q, Li X H, et al. Blood pressure excursion on admission and intravenous thrombolysis in ischemic stroke［J］. J Hypertens, 2023, 41(8): 1265－1270.
［48］Cai W M, Li Y L, Guo K, et al. Association of glycemic variability with death and severe consciousness disturbance among critically ill patients with cerebrovascular disease: analysis of the MIMIC-IV database［J］. Cardiovasc Diabetol, 2023, 22(1): 315.［49］Turan N, Heider R A J, Zaharieva D, et al. Sex differences in the formation of intracranial aneurysms and incidence and outcome of subarachnoid hemorrhage: review of experimental and human studies［J］. Transl Stroke Res, 2016, 7(1): 12－19.
［50］Vlak M H, Algra A, Brandenburg R, et al. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis［J］. Lancet Neurol, 2011, 10(7): 626－636.
［51］Chen Y P, Wright N, Guo Y, et al. Mortality and recurrent vascular events after first incident stroke: a 9-year community-based study of 0·5 million Chinese adults［J］. Lancet Glob Health, 2020, 8(4): e580－e590.
［52］Connolly E S Jr, Rabinstein A A, Carhuapoma J R, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American heart association/American stroke association［J］. Stroke, 2012, 43(6): 1711－1737.
［53］Virani S S, Alonso A, Aparicio H J, et al. Heart disease and stroke statistics－2021 update: a report from the American heart association［J］. Circulation, 2021, 143(8): e254－e743.
［54］Su J B, Cao J, Yang H, et al. Diagnosis of unruptured intracranial aneurysm by high-performance serum metabolic fingerprints［J］. Small Methods, 2023, 7(3): 2201486.
［55］Liu J M, Zhou Y, Li Y, et al. Parent artery reconstruction for large or giant cerebral aneurysms using the tubridge flow diverter: a multicenter, randomized, controlled clinical trial (PARAT)［J］. AJNR Am J Neuroradiol, 2018, 39(5): 807－816.
［56］Zhang H Y, Li L, Zhang H Q, et al. Small and medium-sized aneurysm outcomes following intracranial aneurysm treatment using the pipeline embolization device: a subgroup analysis of the PLUS registry［J］. Front Neurol, 2022, 13: 881353.
［57］Chen J M, Wang L M, Xu H, et al. Meningeal lymphatics clear erythrocytes that arise from subarachnoid hemorrhage［J］. Nat Commun, 2020, 11(1): 3159.

[1]	杨舒悦, 刘思凡, 冀旭, 赵梦冉, 张政, 李鹏. 无镇静胃镜检查后不良反应的危险因素分析[J]. 首都医科大学学报, 2025, 46(4): 676-681.
[2]	张潇文, 唐涛, 李迪, 李深, 席春江. 急性前循环大血管闭塞性脑梗死进展速度的影响因素分析[J]. 首都医科大学学报, 2025, 46(4): 688-693.
[3]	郭宇, 陈伟观, 周三连, 汤莉巧, 孙王妍, 张冬梅, 卢红建. 急性缺血性脑卒中患者血清糖蛋白非转移性黑色素瘤蛋白B蛋白浓度与疾病严重度及预后的相关性分析[J]. 首都医科大学学报, 2025, 46(4): 702-709.
[4]	宋久刚, 王春赛尔, 张倩, 李鹏, 张澍田. 经胃镜取出470例成人食管嵌顿异物临床特点分析[J]. 首都医科大学学报, 2025, 46(3): 576-580.
[5]	国家卫生健康委加强脑卒中防治工作减少百万新发残疾工程专家委员会, 吉训明. 推进国家卫生健康委加强脑卒中防治工作减少百万新发残疾工程：中国脑卒中防治现状与战略[J]. 首都医科大学学报, 2025, 46(1): 11-14.
[6]	王银平, 孟灿灿, 吴文娟, 杨直堂. CD62P、CD40L及节律核受体Rev-erbα在缺血性脑卒中不同发病时间的表达[J]. 首都医科大学学报, 2025, 46(1): 34-40.
[7]	詹艳丽, 李一吟, 李平, 孙景萍, 黄良通, 蔡学礼. 基于区域卒中分级诊疗网络救治急性缺血性脑卒中的现状及疗效分析[J]. 首都医科大学学报, 2025, 46(1): 41-47.
[8]	杨笑, 孟媛媛, 杨靖仪, 王书函, 张立功. 血浆致动脉粥样硬化指数、三酰甘油－葡萄糖指数、脑小血管病影像学标志物对急性缺血性脑卒中患者静脉溶栓早期神经功能恢复的预测价值 [J]. 首都医科大学学报, 2025, 46(1): 48-55.
[9]	张萌, 马咏馨, 贾琼, 张东威, 张昕红, 徐耀铭. 静脉溶栓治疗急性轻型非致残性缺血性脑卒中有效性和安全性的临床观察：一项单中心回顾性观察研究[J]. 首都医科大学学报, 2025, 46(1): 56-62.
[10]	刘肖朦, 周绍娟, 邵小红, 徐文平, 宦峰, 朱向阳. 南通市医防协同管理模式下脑卒中现状及四级预防[J]. 首都医科大学学报, 2025, 46(1): 63-67.
[11]	乔玥, 李传辉, 赵文博. 急性缺血性脑卒中的再灌注治疗的现状与未来[J]. 首都医科大学学报, 2025, 46(1): 68-70.
[12]	李兴茂, 李秀, 王婷, 赵鑫, 王德杨, 商海燕, 赵咏梅, 李森. GLP-1 受体激动剂对 2 型糖尿病患者急性缺血性脑卒中后认知功能的影响[J]. 首都医科大学学报, 2024, 45(6): 1029-1037.
[13]	秦云龙, 周瑾, 刘萌, 罗开发, 王安静, 王頔, 赵晋, 孙世仁. 恶性高血压肾硬化的临床病理特征及预后分析[J]. 首都医科大学学报, 2024, 45(5): 838-845.
[14]	张大坤, 张洪波, 董德鑫, 高翔, 郑瀚, 张浪. 上尿路结石行输尿管镜碎石术后尿源性脓毒血症的早期诊治[J]. 首都医科大学学报, 2024, 45(5): 870-874.
[15]	顾超雄, 李明. 不忘初心，砥砺前行，做科研先锋——中国工程院院士吉训明教授[J]. 首都医科大学学报, 2024, 45(3): 375-378.